Drug Trial Radar · NCT04319198
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Aug 4, 2020
Primary completion
Oct 18, 2024
Study completion Oct 18, 2024
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and how safe it is in participants with metastatic cancer (cancer that has spread).
Conditions
- Metastatic Solid Tumors
Interventions
Sacituzumab Govitecan-hiyDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Any Adverse EventsTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)
- Percentage of Participants Experiencing Any Serious Adverse EventsTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)
- Percentage of Participants Experiencing Any Grade and Grade 3 or 4 Laboratory AbnormalitiesTime frame: First dose date up to 30 days post last dose (Up to 3.9 years)
Locations
21 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Rocky Mountain Cancer Center
Aurora, Colorado
Christiana Care Health Services, Christiana Hospital
Newark, Delaware
Florida Cancer Specialists & Research Institute
Fort Myers, Florida
Baptist Health - Miami Cancer Institute
Miami, Florida
Illinois Cancer Specialists
Arlington Heights, Illinois
University of Chicago
Chicago, Illinois
University of MD Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
New York Cancer & Blood Specialists - Setauket Medical Oncology
Port Jefferson, New York
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Next Oncology
Austin, Texas
Oncology Consultants,P.A.
Houston, Texas
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
Institut Jules Bordet
Brussels, Belgium
CHU UCL NAMUR - Sainte Elisabeth
Namur, Belgium
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Claudius Regaud
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.